NephrologyVideos + slides2026
Harvard Onconephrology Symposium 2026 — kidney injury in the era of immunotherapy, CAR-T and MGRS
The Harvard Onconephrology Symposium 2026 captures two days (17–18 September 2026) of teaching from Brigham and Women’s Hospital and Dana-Farber Cancer Institute on what happens to the kidney when a patient has cancer. Recorded talks and matching slides move from transplant-associated TMA and checkpoint-inhibitor nephritis through cisplatin, CAR-T and GFR estimation to amyloid, myeloma, light-chain cast nephropathy and lymphoproliferative disease after kidney transplant.
- 31sessions
- 2days
- 2course directors
- 2026symposium
What you’ll be able to do
- Work up acute kidney injury after immune checkpoint inhibitors and decide when rechallenge is reasonable
- Recognise and treat HSCT-associated thrombotic microangiopathy
- Dose chemotherapy sensibly when GFR estimates are unreliable
- Limit cisplatin nephrotoxicity and weigh SGLT2 inhibitors and endothelin blockade for protection
- Classify MGRS, amyloid and light-chain cast nephropathy and follow current treatment options
- Manage cancer after kidney transplantation, including post-transplant lymphoproliferative disorders
Inside the course
Transplant, complement and immunotherapy
Day 1 opens with what bone marrow transplant teams want nephrologists to understand, a review of HSCT-TMA diagnosis and treatment, complement biology and lessons from mouse models of interstitial nephritis. A block on checkpoint-inhibitor kidney disease follows, covering ICI-AKI biomarkers, non-renal immune toxicities and a multidisciplinary look at ICI-related glomerulonephritis.
Cellular therapy and cytotoxic drugs
Speakers tackle CAR-T and CAR-Treg toxicities, tumour-infiltrating lymphocyte therapy, magnesium and cisplatin injury, target trial emulation as a research tool, and a case-based talk on choosing chemotherapy doses.
Glomeruli, proteinuria and palliation
The afternoon examines podocyte injury in malignancy, emerging antigens in immune-complex disease, and a four-speaker debate on nephrocentric versus nephrotolerant rechallenge, closing with symptom control and decision support in palliative onconephrology.
Harvard Onconephrology Symposium Day 2: paraproteins
The second day is devoted to plasma-cell disorders: non-AL amyloid, the MGUS-to-myeloma pathway, the IKMG view of MGRS, how immunoglobulins damage the kidney, IgM disease, cast nephropathy beyond plasma exchange, and two transplant MGRS cases, plus cardio-oncology and a quiz-style Jeopardy session.
Built for
- Nephrologists and nephrology fellowsOnconephrology consults are rising, and this program maps the drugs and disorders behind them.
- Oncologists and haematologistsUseful for anticipating renal harm from checkpoint inhibitors, CAR-T and plasma-cell therapies.
- Hospitalists and internistsPractical framing for inpatients with cancer whose creatinine is climbing.
- Transplant nephrologistsDedicated talks on MGRS recurrence and PTLD after kidney transplant.
Faculty & syllabus
Sessions and faculty 31 sessions
- Shruti Gupta; Raad Chowdhury — Welcome From Course Directors
- Joseph Bonventre — Welcome Message from a Pioneer
- Corey Cutler — What Do BMT Docs Wish Nephrologists Knew about HSCT?
- Sumithra Vasu — Changing Diagnostic and Treatment Landscape of HSCT-TMA
- Anuja Java — Cancer and Complementology
- Sandra Herrmann — Murine Models and Immune Therapy: What Can Mice Teach us About AIN?
- Day 1 ICI block — Beyond Biopsy: Biomarkers and Treatments for ICI-AKI
- Sarah Nikiforow — Toxicities of CAR-T and CAR-Treg
- Allison Betof — How Tumor Infiltrating Lymphocytes are Transforming Cancer Treatment
- Edgar Jaimes — MAGnificent Properties of Cisplatin: Mitigating Risk and Managing AKI
- David Leaf — Target Trial Emulation in Onconephrology
- Aisha Shaikh — What’s the GFR!? Current Challenges in Cancer and Future Opportunities
- Abhijat Kitchlu — How Would I Dose Chemotherapy? A Case Review
- Astrid Weins — Podocytes: An Innocent Bystander in Cancer
- Api Chewcharat — Novel Treatments for Proteinuria and Hypertension: Is there a Role for Endothelin Inhibitors?
- María José Soler — SGLT2is: Are they a Miracle For Cancer-Associated Nephrotoxicity Too?
- Sujal Shah — Immune Complex Disease in Cancer: Future of Antigens
- Biruh Workeneh; Astrid Weins; Harish Seethapathy; Aisha Shaikh — Nephrocentric vs Nephrotolerant: When is it Safe to Rechallenge?
- Samantha Gelfand — Palliative Care in Onconephrology: Symptom Management and Decision Support
- Vaishali Sanchorawala — The Other Renal Amyloids: It’s not ALL about AL Amyloid
- Anju Nohria — Pathophysiology of Cancer Therapy and Cardiotoxicity
- Nikhil Munshi — MGUS to Myeloma: Bench to the Bedside
- Samih H. Nasr — IKMG Update on MGRS: Future Associations and Mechanisms
- Christophe Sirac — How do Immunoglobulins Cause Kidney Damage?
- Shruti Gupta; Kenar Jhaveri — The Onconephrology Jeopardy Challenge
- Jorge J. Castillo — How I Manage IgM Disease and Systemic Impact
- Nelson Leung — Light Chain Cast Nephropathy: Beyond Plex (CAR-T, Bispecific)
- Christopher Blosser; Raad Chowdhury — The Clone That Stole the Gift: Transplant MGRS Case Review
- Christopher Blosser — Post Kidney Transplant Lymphoproliferative Disorders: Perspectives from a Transplant Nephrologist
- Raad Chowdhury; Sujal Shah; Nelson Leung; Kenar Jhaveri — The War Against Light Chains: A Case Debate
- Course directors — Final Reflections / Poster Winners
Before you buy
Is every Day 1 checkpoint-inhibitor talk listed by name?
Only the ICI-AKI biomarker lecture has a published title; the non-renal immune toxicity talk and the ICI-GN multidisciplinary discussion are described by topic, so they do not appear separately in the session list.
How large is the download?
No file size or runtime has been published for the 2026 recordings; plan for a multi-gigabyte video set with slide files alongside.
Who leads the program?
Raad Chowdhury, MD, FASN, and Shruti Gupta, MD, MPH, who direct onconephrology at Brigham and Women’s/Dana-Farber, chair both days.
Do I get CME credit or a certificate?
No. Clinicapedia provides the educational content only — no CME or CE credits, MOC points or certificates of completion are included with this product.
Specifications
| Format | Videos + slides |
|---|---|
| Contents | 31 sessions over 2 days |
| Dates | 17–18 September 2026 |
| Hosts | Brigham and Women’s Hospital · Dana-Farber Cancer Institute |
| Publisher | Harvard Medical School |
| Department | Nephrology |
| Delivery | Instant download · lifetime re-download |
Related products
Oncology-Hematology
International Myeloma Society Educational Workshop in Belgrade, Serbia 2026
Oncology-Hematology
The MD Anderson Cancer Center A Comprehensive Board Review in Hematology and Medical Oncology 2025
Cardiology